Nomura Holdings’s Solid Biosciences SLDB Stock Holding History

Nomura Holdings’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-17,914	Closed	-$470K	–	2369
2021 Q4	$470K	Buy	+17,914	New	+$547K	﹤0.01%	1532

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Nomura Holdings's SLDB Position: Q1 2022 in Review

Nomura Holdings sold out of Solid Biosciences (SLDB) in Q1 2022, closing a stake of 17,914 shares — an estimated $470K sold.

Nomura Holdings first reported a position in SLDB in Q4 2021 and held it in 1 quarter. The position peaked at $470K in Q4 2021. 77 funds tracked by Wall St. Rank hold SLDB as of Q1 2022.

Nomura Holdings reported no remaining Solid Biosciences position as of Q1 2022 after selling out during the quarter.
Nomura Holdings sold 17,914 Solid Biosciences shares in Q1 2022, an estimated $470K.
Nomura Holdings first reported a position in Solid Biosciences in Q4 2021 and held it in 1 quarter.
Nomura Holdings's Solid Biosciences position peaked at $470K in Q4 2021.
77 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2022.

Based on Nomura Holdings's 13F filing for Q1 2022, filed 18 May 2022.